reports
Ipsen - Half year statement - 2024 12 31
Ipsen - Half year statement - 2024 12 31 Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF Boulogne-Billancourt (France), January 7th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account: 24,701 shares€2,635,980.25 It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account: 12,751 shares€3,137,934.80 Between July 1st, 2024 and December 31st, 2024 have been exec...
Ipsen - December 2024 - Monthly information relative to the total numb...
Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 December 2024 83,814,526 Gross t...
Ipsen - Bilan semestriel - 31 12 2024
Ipsen - Bilan semestriel - 31 12 2024 Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF Boulogne-Billancourt (France), le 7 janvier 2025 - Au titre du contrat de liquidité confié par IPSEN SA à NATIXIS ODDO BHF, à la date du 31 décembre 2024, les ressources suivantes figuraient au compte de liquidité dédié : 24 701 titres2 635 980,25 euros Il est rappelé que lors de la mise en place du contrat, les moyens suivants figuraient au compte de liquidité dédié : 12 751 titres3 137 934,80 euros Sur la période du 1er juillet 2024 au 31 décembre 2024, ont été exécutées : ...
Ipsen - Décembre 2024 - Information mensuelle relative au nombre total...
Ipsen - Décembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital socialNombre total de droits de vote (1)31 décembre 202483 814 526Total brut* des dro...
- Christophe-Raphaël Ganet
- Christophe-Raphaël Ganet
- Emira Sagaama
- Ghada Ben Sedrine
- Nicolas David
- Oddo Sustainability Team
- Thomas Zlowodzki
SOP SOPRA STERIA GROUP SA
ATO ATOS SE
ROG ROCHE HOLDING LTD
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
LONN LONZA GROUP AG
INF INFOTEL SA
SQI SQLI SA
SWP SWORD GROUP SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
AUB AUBAY SA
ATE ALTEN SA
ZAL ZALANDO SE
GRF GRIFOLS S.A. CLASS A
SAN SANOFI
CAP CAPGEMINI SE
TLX TALANX AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
ITX INDUSTRIA DE DISENO TEXTIL S.A.
BC BRUNELLO CUCINELLI S.P.A.
IDR INDRA SISTEMAS S.A. CLASS A
GRF.P GRIFOLS S.A. PREF CLASS B
AZN ASTRAZENECA PLC
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALG ALLEGRO.EU SA
NA9 NAGARRO
EXN EXCLUSIVE NETWORKS SA
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
- Emira Sagaama
- Ghada Ben Sedrine
- Nicolas David
- Oddo Sustainability Team
- Thomas Zlowodzki
SOP SOPRA STERIA GROUP SA
ATO ATOS SE
ROG ROCHE HOLDING LTD
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
LONN LONZA GROUP AG
INF INFOTEL SA
SQI SQLI SA
SWP SWORD GROUP SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
AUB AUBAY SA
ATE ALTEN SA
ZAL ZALANDO SE
GRF GRIFOLS S.A. CLASS A
SAN SANOFI
CAP CAPGEMINI SE
TLX TALANX AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
ITX INDUSTRIA DE DISENO TEXTIL S.A.
BC BRUNELLO CUCINELLI S.P.A.
IDR INDRA SISTEMAS S.A. CLASS A
GRF.P GRIFOLS S.A. PREF CLASS B
AZN ASTRAZENECA PLC
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALG ALLEGRO.EU SA
NA9 NAGARRO
EXN EXCLUSIVE NETWORKS SA
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
- Team Pharma
- Team Pharma
Ipsen - November 2024 - Monthly information relative to the total numb...
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 30 November 2024 83,814,526 Gross t...
- Charlotte Vaisse
- Christophe-Raphaël Ganet
- Oddo Sustainability Team
- Charlotte Vaisse
- Christophe-Raphaël Ganet
- Oddo Sustainability Team
Ipsen and Biomunex announce exclusive global licensing agreement for f...
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potentialBMX-502 is a bispecific antibody engaging MAIT cells, a subset of non-conventional T cells, and targeting the clinically validated tumor antigen GPC3 to kill cancer cells PARIS, FRANCE; 03 December 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing ...
Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour...
Ipsen et Biomunex annoncent un accord de licence mondial exclusif pour un activateur de cellules MAIT, une nouvelle classe thérapeutique en immuno-oncologie Ipsen obtient les droits mondiaux exclusifs pour développer, fabriquer et commercialiser le BMX-502, un nouvel activateur de lymphocytes T (TCE, « T cell engagers ») en préclinique, avec un potentiel de premier de sa classe thérapeutique (« first-in-class »).Le BMX-502 est un anticorps bispécifique qui cible les cellules MAIT, un sous-ensemble de lymphocytes T non conventionnels, ainsi que l’antigène tumoral cliniquement validé GPC3 pou...
- Dominic Rose
- Naresh Chouhan
EU Pharma 2025 Outlook - The Correction Was Due, Tread Carefully
In the aftermath of the H224 Healthcare correction, we look forward to 2025 with a more focused stock specific approach We show sector fundamentals have remained robust despite the correction. We see 4 key themes for the Pharma sector in 2025; 1) 2025 is a very strong year for important pipeline readouts, 2) The volume impact of Medicare Part D reform will dominate the narrative in H125 & continue to be a tailwind into 2026, 3) Margin expansion should be robust at a sector level, 4) Biotech M&A...
AstraZeneca: 1 director
A director at AstraZeneca bought 1,500 shares at 126.796USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Bylvay® (odevixibat) data shows sustained improvement in severe itch a...
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Famili...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.